Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : License crawled time : 00:00 save search
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Published: 2024-03-31 (Crawled : 00:00) - prnewswire.com
BIIB | $190.59 0.04% 50K
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
leqembi fda disease license treatment alzheimer's application submission
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
Published: 2024-02-15 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 0.11% -1.11% 10K
|
Manufacturing
|
| O: -2.99%
H: 3.82%
C: 3.54%
license research therapeutics agreement
Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
Published: 2024-01-22 (Crawled : 00:00) - globenewswire.com
GMAB | $28.33 -0.7% -0.74% 360
|
Health Technology
|
| O: -2.23%
H: 0.0%
C: -0.29%
GNMSF | $290.38 3.33% 3.83% 0
|
Health Technology
|
| O: -0.91%
H: 0.0%
C: -1.15%
JNJ | News | $145.74 0.67% -0.36% 8.1K
|
Health Technology
|
| O: -1.11%
H: 0.0%
C: 0.0%
license agreement
Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.
Published: 2024-01-08 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.17 -4.42% 0
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: -3.88%
ALPMY | $9.47 0.11% -1.11% 10K
|
Manufacturing
|
| O: -1.22%
H: 0.0%
C: -0.72%
license update application
Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease
Published: 2023-12-11 (Crawled : 00:00) - biospace.com/
SNYNF | News | $92.7 0
|
Health Technology
|
| O: 0.5%
H: 1.67%
C: 0.1%
SNY | News | $45.39 47K
|
Health Technology
|
| O: 2.15%
H: 0.0%
C: 0.0%
mze001 disease license collaboration therapeutics potential agreement therapy sanofi
Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
Published: 2023-08-04 (Crawled : 00:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 570
|
Health Technology
|
| O: -63.91%
H: 14.58%
C: 13.89%
drug disease children license food application response
China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab
Published: 2023-07-31 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 0.11% -1.11% 10K
|
Manufacturing
|
| O: -0.89%
H: 0.0%
C: -0.21%
license medical application
Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets
Published: 2023-07-10 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 0.11% -1.11% 10K
|
Manufacturing
|
| O: 1.25%
H: 0.07%
C: -0.21%
FDMT | News | $24.78 -2.05% -2.39% 100
|
Health Technology
|
| O: 2.03%
H: 3.71%
C: 3.24%
rare license therapeutics agreement molecular
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
Published: 2023-04-20 (Crawled : 00:00) - globenewswire.com
GNMSF | $290.38 3.33% 3.83% 0
|
Health Technology
|
| O: 1.53%
H: 1.41%
C: 1.18%
JNJ | News | $145.74 0.67% -0.36% 8.1K
|
Health Technology
|
| O: 0.53%
H: 0.32%
C: -1.06%
GMAB | $28.33 -0.7% -0.74% 360
|
Health Technology
|
| O: 0.1%
H: 0.96%
C: 0.64%
license agreement
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
Published: 2023-04-18 (Crawled : 00:00) - biospace.com/
FNCH | $2.36 -6.35% -9.57% 290
|
Professional, Scientific, and T...
|
| O: -5.18%
H: 7.24%
C: 7.14%
license hospital collaboration therapeutics agreement
Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer
Published: 2023-03-09 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 0.11% -1.11% 10K
|
Manufacturing
|
| O: 0.32%
H: 0.46%
C: -0.32%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.0%
H: 0.2%
C: -0.59%
medical application license cancer
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Published: 2023-03-05 (Crawled : 00:00) - globenewswire.com
BIIB | $190.59 0.04% 50K
|
Health Technology
|
| O: 0.09%
H: 0.79%
C: -0.09%
treatment fda disease application grants license approval alzheimer’s review
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Published: 2023-02-27 (Crawled : 00:00) - globenewswire.com
BIIB | $190.59 0.04% 50K
|
Health Technology
|
| O: -0.53%
H: 1.02%
C: 0.78%
lecanemab medical application license review china
Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)
Published: 2023-01-31 (Crawled : 00:00) - globenewswire.com
MESO | $5.11 2.0% 2.53% 570
|
Health Technology
|
| O: 9.09%
H: 3.61%
C: -0.28%
fda disease children application license
THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Published: 2022-07-05 (Crawled : 00:00) - prnewswire.com
BIIB | $190.59 0.04% 50K
|
Health Technology
|
| O: 1.98%
H: 1.73%
C: 1.35%
fda disease alzheimer's application grants license approval review lecanemab
EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Published: 2022-05-09 (Crawled : 00:00) - prnewswire.com
BIIB | $190.59 0.04% 50K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
fda disease alzheimer's application license approval submission alzheimer’s lecanemab
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
Published: 2022-04-10 (Crawled : 00:00) - prnewswire.com
LLY | $745.95 -0.64% -0.13% 17K
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
license
Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
Published: 2022-04-07 (Crawled : 00:00) - globenewswire.com
GNMSF | $290.38 3.33% 3.83% 0
|
Health Technology
|
| O: -0.01%
H: 0.81%
C: -2.32%
JNJ | News | $145.74 0.67% -0.36% 8.1K
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: 0.0%
HALO M | $37.81 -0.55% -0.48% 14
|
Health Technology
|
| O: -0.81%
H: 1.85%
C: 0.96%
GMAB | $28.33 -0.7% -0.74% 360
|
Health Technology
|
| O: -3.97%
H: 1.08%
C: -0.86%
license
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
Published: 2022-02-10 (Crawled : 00:00) - biospace.com/
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
commercialization linzagolix license
Access Advance Welcomes ZTE as a Licensor and Licensee of the HEVC Advance Patent Pool
Published: 2021-11-17 (Crawled : 00:00) - prnewswire.com
ZTCOF | $1.91 -4.02% 0
|
Electronic Technology
|
| O: 0.71%
H: 6.74%
C: 6.74%
patent license
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
AGBA | News | $1.4 250.0% 35M
|
Finance
RWOD | $12.0 50.06% 3.9M
|
n/a
INDO | $4.9 20.1% 2.2M
|
Energy Minerals
NURO | $4.32 18.36% 66K
|
Health Technology
HUBC | $1.52 17.83% 4.7M
|
n/a
MCB 4 | $38.545 16.45% 34K
|
Finance
CARV 4 | $1.77 11.32% 8.5K
|
Finance
SWVL | $10.51 10.87% 40K
|
n/a
BROG | $1.23 10.81% 320K
|
Finance
PARA | $12.03 9.66% 5.8M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.